response genetics inc. Resources | BNET
On The Insider: Sexiest Magazine Covers of All Time

BNET Industries

Response Genetics Inc. (RGDX) is in the Pharma Industry

Revenue
Dec 31 2007
$7.7M
Profit
Dec 31 2007
($5.0M)
Market Cap
Oct 13 2008
$27.9M

Latest News and Analysis

  • Response Genetics, Inc. Update Call Transcript

    Question-and-Answer SessionOperator Thank you. We will now be conducting a question and answer session. Operator Instructions One moment please, while we pull for questions. Our first question comes from Zarak Khurshid with Caris & Company. Please proceed with your questions. Zarak Khurshid-Caris & Company Thanks. Hi Kathy and Tom,...

    Earnings calls 2008-03-26

    Tags: Response Genetics Inc.

Additional Resources

  • page 1 of 1
  • Incorporated: 1999
  • CEO: Ms. Kathleen Danenberg
  • Employees: 37

Response Genetics is engaged in the research and development of its own pharmacogenomic diagnostic tests based on one of its proprietary technologies. Co.'s proposed products are targeted for potential use in the treatment of cancer. Co. generate revenues from sales of pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry using its proprietary technologies, RG-1 and RG-2. Using Co.'s patented and proprietary technologies, Co. extracts nucleic acids such as RNA and DNA from tumor specimens preserved in paraffin, a wax-like substance, in order to perform phamacogenomic analysis.

Key Competitors

advertisement
Response Genetics Inc. Company Info

Board of Directors

Mr. Tom DeMeester M.D.

Chairman

Mr. David M. Smith

Vice-Chairman

Mr. Kirk Calhoun

Mr. David Gandara

Mr. Gary Nusbaum

Ms. Kathleen Danenberg

Mr. Michael Serruya

Mr. John C. Ferrara

Contact Information

1640 Marengo Street

Los Angeles, CA

http://www.responsegenetics.com

323 224-3900

NAICS Code

In-Vitro Diagnostic Substance Manufacturing: 325413
advertisement